Target Information
| Target General Information | Top | |||||
|---|---|---|---|---|---|---|
| Target ID |
T96723
|
|||||
| Target Name |
SF3b complex (SF3b)
|
|||||
| Gene Name |
SF3B1-SF3B2-SF3B3-SF3B4-SF3B5-SF3B6
|
|||||
| Target Type |
Clinical trial target
|
[1] | ||||
| Disease | [+] 3 Target-related Diseases | + | ||||
| 1 | Acute myeloid leukaemia [ICD-11: 2A60] | |||||
| 2 | Chronic myelomonocytic leukaemia [ICD-11: 2A40] | |||||
| 3 | Myelodysplastic syndrome [ICD-11: 2A37] | |||||
| UniProt ID | ||||||
| Drugs and Modes of Action | Top | |||||
|---|---|---|---|---|---|---|
| Clinical Trial Drug(s) | [+] 1 Clinical Trial Drugs | + | ||||
| 1 | H3B-8800 | Drug Info | Phase 1 | Myelodysplastic syndrome | [2] | |
| Mode of Action | [+] 1 Modes of Action | + | ||||
| Modulator | [+] 1 Modulator drugs | + | ||||
| 1 | H3B-8800 | Drug Info | [1] | |||
| Drug Binding Sites of Target | Top | |||||
|---|---|---|---|---|---|---|
| Ligand Name: Adenine | Ligand Info | |||||
| Structure Description | Branch Recognition by SF3b14 | PDB:3LQV | ||||
| Method | X-ray diffraction | Resolution | 2.38 Å | Mutation | No | [3] |
| PDB Sequence |
LPPEVNRILY
22 IRNLPYKITA32 EEMYDIFGKY42 GPIRQIRVGN52 TPETRGTAYV62 VYEDIFDAKN 72 AVDHLSGFNV82 SNRYLVVLYY92 NANRAFQKMD102 TKKKEEQLKL112 LKEKYGINTD 122 PPK
|
|||||
|
|
||||||
| Click to View More Binding Site Information of This Target with Different Ligands | ||||||
| References | Top | |||||
|---|---|---|---|---|---|---|
| REF 1 | Clinical pipeline report, company report or official report of H3 Biomedicine. | |||||
| REF 2 | ClinicalTrials.gov (NCT02841540) A Study of H3B-8800 in Participants With Myelodysplastic Syndromes, Acute Myeloid Leukemia, and Chronic Myelomonocytic Leukemia. U.S. National Institutes of Health. | |||||
| REF 3 | Structural model of the p14/SF3b155 branch duplex complex. RNA. 2011 Jan;17(1):155-65. | |||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.